MA49047A - Composés inhibiteurs d'ask1 et utilisations associées - Google Patents
Composés inhibiteurs d'ask1 et utilisations associéesInfo
- Publication number
- MA49047A MA49047A MA049047A MA49047A MA49047A MA 49047 A MA49047 A MA 49047A MA 049047 A MA049047 A MA 049047A MA 49047 A MA49047 A MA 49047A MA 49047 A MA49047 A MA 49047A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- ask1 inhibitor
- associated uses
- ask1
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762482085P | 2017-04-05 | 2017-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49047A true MA49047A (fr) | 2020-02-12 |
Family
ID=63712299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049047A MA49047A (fr) | 2017-04-05 | 2018-04-04 | Composés inhibiteurs d'ask1 et utilisations associées |
Country Status (31)
Country | Link |
---|---|
US (2) | US20210087167A1 (fr) |
EP (1) | EP3606519B1 (fr) |
JP (1) | JP7196093B2 (fr) |
KR (1) | KR102665145B1 (fr) |
CN (1) | CN110730661B (fr) |
AR (1) | AR111407A1 (fr) |
AU (1) | AU2018250217B2 (fr) |
BR (1) | BR112019021021A2 (fr) |
CA (1) | CA3059107A1 (fr) |
CL (1) | CL2019002810A1 (fr) |
CO (1) | CO2019011708A2 (fr) |
CR (1) | CR20190503A (fr) |
CU (1) | CU20190080A7 (fr) |
DK (1) | DK3606519T3 (fr) |
DO (1) | DOP2019000255A (fr) |
EA (1) | EA201992299A1 (fr) |
EC (1) | ECSP19078393A (fr) |
FI (1) | FI3606519T3 (fr) |
IL (1) | IL269711B (fr) |
JO (1) | JOP20190221A1 (fr) |
MA (1) | MA49047A (fr) |
MX (1) | MX2019012013A (fr) |
NI (1) | NI201900102A (fr) |
NZ (1) | NZ758345A (fr) |
PE (1) | PE20200009A1 (fr) |
PH (1) | PH12019502288A1 (fr) |
PT (1) | PT3606519T (fr) |
RU (1) | RU2019134679A (fr) |
SG (1) | SG11201909155VA (fr) |
TW (1) | TWI779022B (fr) |
WO (1) | WO2018187506A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10787435B2 (en) * | 2017-01-22 | 2020-09-29 | Fuijan Cosunter Pharmaceutical Co. Ltd. | ASK1 inhibitor and preparation method and use thereof |
MX2019013275A (es) | 2017-05-12 | 2020-07-27 | Enanta Pharm Inc | Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos. |
US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
IL278368B2 (en) | 2018-05-02 | 2024-06-01 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods for its use |
WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020106707A1 (fr) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation |
US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
JP2023514019A (ja) | 2019-12-27 | 2023-04-05 | ルピン・リミテッド | 置換三環式化合物 |
KR20230003128A (ko) | 2020-05-01 | 2023-01-05 | 화이자 인코포레이티드 | Hpk1 억제제로서의 아잘락탐 화합물 |
WO2021224818A1 (fr) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Composés d'isoindolone en tant qu'inhibiteurs de hpk1 |
WO2024020458A1 (fr) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
RS53176B (en) * | 2010-02-03 | 2014-06-30 | Takeda Pharmaceutical Company Limited | KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS |
WO2012079022A1 (fr) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Dérivés de dioxopipéridinylphtalimide substitué |
JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ask1阻害ピロロピリミジン誘導体 |
EP3524243A1 (fr) * | 2014-09-24 | 2019-08-14 | Gilead Sciences, Inc. | Procédés de traitement des maladies du foie |
WO2017214359A1 (fr) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Nouveaux inhibiteurs de toxine de clostridium difficile |
US10787435B2 (en) * | 2017-01-22 | 2020-09-29 | Fuijan Cosunter Pharmaceutical Co. Ltd. | ASK1 inhibitor and preparation method and use thereof |
SG11201906579UA (en) | 2017-01-22 | 2019-08-27 | Fujian Cosunter Pharmaceutical Co Ltd | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
EP3580224B1 (fr) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Agents inhibiteurs d'ask1 |
WO2018149284A1 (fr) | 2017-02-16 | 2018-08-23 | 四川科伦博泰生物医药股份有限公司 | Inhibiteur de kinase, son procédé de préparation et son utilisation |
WO2018151830A1 (fr) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
WO2018157277A1 (fr) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Composés d'isoquinoléine et de naphtydrine |
TW201833108A (zh) | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | 醯胺類衍生物抑制劑及其製備方法和應用 |
US11345676B2 (en) | 2017-03-27 | 2022-05-31 | Pharmakea, Inc. | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds |
WO2019055540A1 (fr) | 2017-09-13 | 2019-03-21 | D.E. Shaw Research, Llc | Composés utilisés comme inhibiteurs de ras et leur utilisation |
WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 BR BR112019021021A patent/BR112019021021A2/pt active Search and Examination
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/fr unknown
- 2018-04-04 MX MX2019012013A patent/MX2019012013A/es unknown
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active IP Right Grant
- 2018-04-04 CA CA3059107A patent/CA3059107A1/fr active Pending
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/fr active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es unknown
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49047A (fr) | Composés inhibiteurs d'ask1 et utilisations associées | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
MA50173A (fr) | Composés activateurs de bisamide sarcomère et leurs utilisations | |
MA47420A (fr) | Composés inhibiteurs d'oga | |
UA42295S (uk) | Комп'ютер | |
MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
MA46589A (fr) | Composés et utilisations de ces derniers | |
MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
MA45857A (fr) | Composés et compositions, et utilisations associées | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA52365A (fr) | Composés et leurs utilisations | |
MA48956A (fr) | Composés mic-1 et utilisations associées | |
UA42369S (uk) | Комп'ютер | |
MA55385A (fr) | Composés et leurs utilisations | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
MA52092A (fr) | Composés et leurs utilisations | |
MA41495A (fr) | Composés benzoxaborole et leurs utilisations | |
MA44968A (fr) | Esters d'oxaborole et leurs utilisations | |
MA54829A (fr) | Composés et leurs utilisations |